Avidity Biosciences (RNA) News Today $26.07 -0.19 (-0.73%) Closing price 03:59 PM EasternExtended Trading$26.50 +0.43 (+1.66%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period 3RNA : 12 Analysts Assess Avidity Biosciences: What You Need To KnowMay 7 at 6:38 PM | benzinga.comFirst Trust Advisors LP Buys 45,254 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)First Trust Advisors LP lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 110.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 86,395 shares of the biotechnology company's stock after acquiring an additional 45,254 sharesMay 7 at 3:39 AM | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferenceMay 6 at 9:00 AM | prnewswire.comFreestone Grove Partners LP Takes $523,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Freestone Grove Partners LP acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,971 shares of the biotechnolMay 6 at 4:56 AM | marketbeat.comBoxer Capital Management LLC Buys New Shares in Avidity Biosciences, Inc. (NASDAQ:RNA)Boxer Capital Management LLC purchased a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,727,388 shares of the biotMay 4 at 6:25 AM | marketbeat.comAvidity Biosciences (RNA) Expected to Announce Quarterly Earnings on ThursdayAvidity Biosciences (NASDAQ:RNA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-avidity-biosciences-inc-stock/)May 3, 2025 | marketbeat.comKathleen P. Gallagher Sells 5,875 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 3, 2025 | insidertrades.com60,641 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Aquatic Capital Management LLCAquatic Capital Management LLC acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 60,641 shares of the biotechnology cMay 1, 2025 | marketbeat.comInvesco Ltd. Lowers Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Invesco Ltd. trimmed its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 69.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,763 shares of the biotechnologyApril 30, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Tower Research Capital LLC TRC raised its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2,044.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,029 sharesApril 29, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD grew its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,042,823 shares of theApril 28, 2025 | marketbeat.comLPL Financial LLC Increases Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)LPL Financial LLC increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 273.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,726 shares of the biotechnology cApril 28, 2025 | marketbeat.comMarshall Wace LLP Has $4.74 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Marshall Wace LLP decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 10.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 162,863 shares of the biotechnology company's stock afteApril 27, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Raymond James Financial Inc. bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 198,907 shares of the biotechnology company's stock, valued at approxApril 27, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 327,430 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Adage Capital Partners GP L.L.C. lessened its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 10.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,751,944 shares of the biotechnology company'sApril 26, 2025 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Takes $1.60 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 55,113 shares of the biotechnoloApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Has $15.81 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Silverarc Capital Management LLC grew its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 14.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 543,651 shares of the biotechnology company's stock after purchasing an addApril 24, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Up 5.7% - Should You Buy?Avidity Biosciences (NASDAQ:RNA) Trading Up 5.7% - What's Next?April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Grows Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Avoro Capital Advisors LLC lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 9.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,500,000 shares of the biotechnology company's stock after bApril 23, 2025 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 21, 2025 | prnewswire.comRenaissance Technologies LLC Acquires 69,300 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Renaissance Technologies LLC lifted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 48.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 211,200 shares of the biotechApril 21, 2025 | marketbeat.comFederated Hermes Inc. Decreases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Federated Hermes Inc. decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 94.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,577 shares of the biotechnology company's stock after selling 25,557 shareApril 21, 2025 | marketbeat.comJump Financial LLC Acquires Shares of 95,575 Avidity Biosciences, Inc. (NASDAQ:RNA)Jump Financial LLC bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 95,575 shares of the biotechnology company's sApril 20, 2025 | marketbeat.comWalleye Capital LLC Takes $2.67 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Walleye Capital LLC acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 91,935 shares of the biotechnology company's stock, valued at approximately $2,April 20, 2025 | marketbeat.comAlliancebernstein L.P. Cuts Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Alliancebernstein L.P. trimmed its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 25.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,770 shares of the biotechnology company's stock after sellingApril 16, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. reduced its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 450,144 shares of the biotechApril 15, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have earned an average recommendation of "Buy" from the thirteen research firms that are covering the firm, MarketBeat reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 12 montApril 14, 2025 | marketbeat.comExodusPoint Capital Management LP Makes New $984,000 Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)ExodusPoint Capital Management LP bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 33,844 shares of the biotechnoloApril 13, 2025 | marketbeat.comGeode Capital Management LLC Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Geode Capital Management LLC boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,807,455 shares ofApril 13, 2025 | marketbeat.comFmr LLC Trims Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Fmr LLC trimmed its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,509,606 shares of the biotechnology company's stock after sellingApril 12, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low - Here's WhyAvidity Biosciences (NASDAQ:RNA) Sets New 1-Year Low - Should You Sell?April 12, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Takes $402,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Dynamic Technology Lab Private Ltd acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,830 shares of the biotechnologyApril 12, 2025 | marketbeat.comBeyond The Numbers: 13 Analysts Discuss Avidity Biosciences StockApril 11, 2025 | nasdaq.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Should You Sell?Avidity Biosciences (NASDAQ:RNA) Shares Gap Down - What's Next?April 11, 2025 | marketbeat.comAvidity Biosciences' (RNA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Avidity Biosciences in a research note on Wednesday.April 11, 2025 | marketbeat.comTrexquant Investment LP Acquires 60,685 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Trexquant Investment LP raised its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 383.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,495 shares of the biotechnology cApril 11, 2025 | marketbeat.comSei Investments Co. Sells 19,149 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Sei Investments Co. trimmed its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 47.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,554 shares of the biotechnology company's stock after selling 19,April 10, 2025 | marketbeat.com5RNA : Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences StockApril 9, 2025 | benzinga.comAvidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1April 8, 2025 | prnewswire.comFinepoint Capital LP Takes $11.38 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Finepoint Capital LP purchased a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 391,300 shares of the biotechnology company's stock,April 8, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Schroder Investment Management GroupSchroder Investment Management Group boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 99.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,480 shares of the bioApril 8, 2025 | marketbeat.comNorges Bank Invests $21.08 Million in Avidity Biosciences, Inc. (NASDAQ:RNA)Norges Bank bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 724,787 shares of the biotechnology company's stocApril 8, 2025 | marketbeat.com14,044 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Bryce Point Capital LLCBryce Point Capital LLC purchased a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 14,044 shares of the biotechnology company's stock, valued at approximately $408,0April 7, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. grew its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,431,911 shares of the biotechnology company'sApril 6, 2025 | marketbeat.comAvidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your MoneyApril 5, 2025 | msn.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $163,501.25 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Kathleen P. Gallagher sold 5,875 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $27.83, for a total transaction of $163,501.25. Following the completion of the transaction, the insider now owns 50,554 shares of the company's stock, valued at approximately $1,406,917.82. The trade was a 10.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.April 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Takes $521,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)KLP Kapitalforvaltning AS acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,900 shares ofApril 5, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Still a Buy?Avidity Biosciences (NASDAQ:RNA) Stock Price Up 4.1% - Here's WhyApril 4, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Wellington Management Group LLPWellington Management Group LLP boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 15.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,106,097 shares of the biotechnology company's stock after purchasing an additionalApril 3, 2025 | marketbeat.comAvidity Biosciences completes enrollment in Phase 1/2 Fortitude trialApril 2, 2025 | markets.businessinsider.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.920.64▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼97▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNA Stock Free RNA Stock Alerts